First-in-Class ADC Expands Portfolio of Precision Therapies in Bladder Cancer

Rachel Narozniak, MA
Published: Friday, Feb 28, 2020
Bradley A. McGregor, MD

Bradley A. McGregor, MD
The bladder cancer armamentarium gained a powerful agent in December 2019 with the approval of enfortumab vedotin-ejfv (Padcev), a Nectin-4–directed antibody-drug conjugate (ADC). The agency granted accelerated approval to the firstin- class agent for adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1/PD-L1 inhibitor and a platinum-containing chemotherapy in the neoadjuvant, adjuvant, locally advanced, or metastatic setting. The decision was based on the tumor response rate observed in the phase II single-arm EV-201 trial (NCT03219333).

Enfortumab vedotin “is a new standard of care” for patients whose disease progresses after prior immunotherapy and platinum-based therapy, said Bradley McGregor, MD, an investigator of the EV-201 study, in an interview with OncLive®.

McGregor, a hematologist/oncologist and the clinical director of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts, discussed enfortumab vedotin-ejfv’s path to approval and its future potential in bladder cancer.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication